Navigation Links
ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program
Date:8/6/2009

esistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE, and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward-looking statements in this press release include statements regarding ViroPharma's clinical development programs, including statements that NTCD may significantly reduce the incidence of recurrent disease for patients with CDI. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. The development and commercialization of pharmaceutical products is subject to risks and uncertainties. The studies described in this press release represent the initial human studies with NTCD and the results of these studies may not support any or all of the statements in this press release. There can be no assurance that our Phase
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... New York, NY (PRWEB) July 12, 2014 ... experienced steady growth over the past five years, buoyed ... the agricultural sector's supply management system. “Eggs are a ... a result, per capita egg consumption generally grows in ... IBISWorld Industry Analyst Will McKitterick. Furthermore, demand for new ...
(Date:7/12/2014)... Miami, FL (PRWEB) July 12, 2014 Fresh ... Brazil and Colombia will meet on September 5th at ... allowed the world to see some of the brightest stars ... Diehard soccer fans in Miami will be treated to some ... , Brazil is currently ranked as the third best team ...
(Date:7/12/2014)... The report, "Phthalic Anhydride and Derivatives (Plasticizers, ... & Geography – Trends & Forecast to 2018," defines ... of market volume and value. The report also estimates ... market of phthalic anhydride is projected to grow from ... by 2018, with a CAGR of 5.24% from 2013 ...
(Date:7/12/2014)... 12, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
(Date:7/12/2014)... Response Management Systems is a crucial peak load management ... energy supply and demand. With the help of DRMS, ... increasing pressure on the grid) and replaced by Advanced ... and thermostats for load reduction. , DRMS is ... government mandates and benefits for energy efficiency and conservation ...
Breaking Medicine News(10 mins):Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4
... 7 , 2010 in the World Journal of ... clinical trial, the authors examined if acupuncture could prevent ... with colon cancer in Shanghai, China. Acupuncture did not ... who developed PPOI also suggested acupuncture was not useful ...
... People with Parkinson,s Disease are more likely to display ... circumstances if they are pathological gamblers, according to research ... of Neurology . A number of studies have ... is a frequent impulse control disorder associated mainly with ...
... incidence of colon cancer worldwide. The new study analyses ... between 1951 and 2006 in terms of certain changes ... vegetables...) and also behaviour (physical exercise, sedentary lifestyles). ... Cancer Prevention , show that mortality due to colon ...
... provide the perfect balance between stability and movement in ... partnership begins in the embryo, when the bones are ... issue of Developmental Cell , describes a previously ... development of a strong skeletal system. ,Our ...
... A simple and inexpensive eye test could aid detection and ... earlier stage than is currently possible, according to new research ... Cordeiro & Stephen Moss and published today in Cell ... retinal, and therefore brain cell death, to be directly measured ...
... linked to cholesterol-lowering effect, study suggests , THURSDAY, Jan. ... of the effect of statin drug therapy on the ... used drugs. , Much of the benefit from statins ... the drugs, lowering of blood levels of "bad" LDL ...
Cached Medicine News:Health News:Does electro-acupuncture prevent prolonged postoperative ileus? 2Health News:Parkinson's patients who are pathological gamblers also display abnormal social behavior 2Health News:The first map of colon cancer in Spain is published 2Health News:Weizmann Institute scientists reveal how tendons shape developing bones 2Health News:Seeing a diagnosis: How an eye test could aid Alzheimer's detection 2Health News:More Evidence That Statins Cut Stroke Risk 2Health News:More Evidence That Statins Cut Stroke Risk 3
(Date:7/11/2014)... -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI ), ... and Drug Administration ("FDA"), has notified the Company that ... Drug ("IND") application before granting the Company permission to ... Dr. Chris Chapman , RCP,s President, commented, "We ... When we receive the agency,s official comments and/or recommendations, ...
(Date:7/11/2014)... -- According to a new market ... Application (Healthcare, Homeland security, Industrial application, Nuclear Power ... Instruments, Fixed, and Installed Instruments) & Geography - ... MarketsandMarkets, the Scintillator Market is expected to grow ... 2020, and reach $479.16 Million in 2020. ...
(Date:7/11/2014)... 11, 2014  Kindred Hospital Houston Northwest, with ... opening of its new outpatient wound healing center.  ... people with chronic, hard to heal wounds. Chronic ... to amputation, lower leg wounds related to blood ... and traumatic injury wounds which are complex and ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2
... CENTER VALLEY, Pa., Oct. 25, 2011 Olympus America ... and a new 5mm HD deflectable videolaparoscope, the ENDOEYE ... 97th Annual Clinical Congress in San Francisco. The VISERA ... advanced image processing to provide the best possible image ...
... Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH ... serious diseases associated with inflammation, today announced it ... study.  PEARL-SC (A randomized, double-blind Phase 2b study ... blisibimod administration in subjects with systemic lupus erythematosus) ...
Cached Medicine Technology:Olympus Introduces World's First Autoclavable 5mm HD Deflectable Videolaparoscope 2Olympus Introduces World's First Autoclavable 5mm HD Deflectable Videolaparoscope 3Anthera Announces Last Patient Enrolled in PEARL-SC Study 2Anthera Announces Last Patient Enrolled in PEARL-SC Study 3Anthera Announces Last Patient Enrolled in PEARL-SC Study 4
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
Used for intermittent catheterization of a male or female patient to provide drainage of urine from the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: